Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform. Blue Ledge Capital, Evolution VC Partners, Vice Ventures and Gaingels led the financing. It brings Richmond, Virginia-based Qnovia to $50 million raised since inception. Funds raised by Qnovia support its proprietary inhaled drug delivery platform, the […]
Respiratory
CSA Medical raises $53M to support metered cryospray tech
CSA Medical announced today that it completed an oversubscribed Series D preferred stock equity financing worth $53 million. TVM Capital Life Science and Yonjin Ventures co-led the funding round. Existing shareholders SV Health Investors, Ascension Ventures, First Analysis, Blue Heron and Intersouth Partners also participated. In connection with the financing, Dr. Luc Marengere of TVM […]
Medline launches new medication delivery nebulizer
Medline announced that it launched its Hudson RCI TurboMist small-volume nebulizer for delivering medication in respiratory care. TurboMist can deliver medication in just three minutes, making it the fastest small-volume nebulizer on the market, Medline says. Traditional nebulizers, meanwhile, can take at least 10 minutes to provide treatment. Medline designed TurboMist to deliver 2.5 times […]
Qnovia has positive results for inhaled smoking cessation therapy
Qnovia announced positive results from its first-in-human study for the QN-01 inhaled smoking cessation therapy. Richmond, Virginia-based Qnovia develops the RespiRx drug delivery platform that leverages a vibrating mesh nebulizer. CEO Brian Quigley explained the technology to Drug Delivery Business News last year. The company designed the QN-01 therapy to meet the need for safe and effective […]
Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine
Researchers at McMaster University in Canada announced that they received $8.2 million from the Canadian Institutes of Health Research (CIHR). Fiona Smaill picked up $8.2 million to advance an inhaled COVID-19 vaccine through to Phase 2 human trials. The trials will evaluate the safety and immunogenicity of the next-generation vaccine delivered by inhaled aerosol. Her […]
Vero Biotech raises $30M for tankless nitric oxide delivery system
Vero Biotech announced today that it raised $30 million to support its Genosyl inhaled nitric oxide (iNO) delivery system. The financing comes just days after the company received FDA approval for Genosyl. The third-generation Genosyl delivery system features faster dosing, simpler workflow and operational efficiency. Petrichor, a healthcare-dedicated growth capital provider, led the financing. Atlanta-based […]
How Qnovia aims to use inhaled therapeutics for smoking cessation
Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery. Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business. In July 2020, he joined founder and then-CEO at Qnovia (then […]
Qnovia raises $17M Series A for inhaled therapeutics pipeline
Qnovia announced today that it raised $17 million in a Series A financing to support its inhaled therapeutics technologies. Blue Ledge Capital led the offering. DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures also participated. Los Angeles-based Qnovia develops inhaled therapeutics. It focuses on nicotine replacement therapy (NRT) and cardiopulmonary diseases. Qnovia […]
Philip Morris hires two former FDA officials as it pushes ‘smoke-free’ development
Cigarette maker Philip Morris (NYSE:PM) announced today that it appointed two former FDA officials to leadership positions. Dr. Badrul Chowdhury is the company’s new chief life sciences officer for smoke-free products. Dr. Matthew Holman joins as VP of U.S. scientific engagement and regulatory strategy. Both appointments fall in line with the company’s efforts to push […]
Lyra Therapeutics enrolls first patient in Phase 3 chronic rhinosinusitis trial
Lyra Therapeutics (Nasdaq:LYRA) announced today that it enrolled the first patient in its Phase 3 Enlighten II clinical trial. Enlighten II is evaluating the company’s LYR-210 in adult patients with chronic rhinosinusitis (CRS). Lyra’s proprietary XTreo platform delivers LYR-210. Watertown, Massachusetts-based Lyra designed the proprietary XTreo platform for precise, sustained and local delivery. The platform […]
